Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Revenue From Contracts With Customers (Tables)

v3.22.2.2
Note 3 - Revenue From Contracts With Customers (Tables)
9 Months Ended
Sep. 30, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 

Sales revenue:

                               

Tc99m tilmanocept - Europe

  $ 7,516     $     $ 14,035     $  
                                 

License revenue:

                               

Tc99m tilmanocept - Europe

  $     $ 9,116     $     $ 44,665  
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]
   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2022

   

2021

   

2022

   

2021

 
Total deferred revenue related to contracts with customers, beginning of period   $ 700,000     $ 700,000     $ 700,000     $ 700,000  

Deferred revenue related to milestones achieved

                100,000        

Deferred revenue related to milestones achieved, written off due to contract renegotiations

                (100,000

)

     
Total deferred revenue related to contracts with customers, end of period   $ 700,000     $ 700,000     $ 700,000     $ 700,000